Skip to Main content Skip to Navigation
Journal articles

Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.

Abstract : Development of kinase-targeted therapies for central nervous system (CNS) diseases is a great challenge. Glycogen synthase kinase 3 (GSK-3) offers a great potential for severe CNS unmet diseases, being one of the inhibitors on clinical trials for different tauopathies. Following our hypothesis based on the enhanced reactivity of residue Cys199 in the binding site of GSK-3, we examine here the suitability of phenylhalomethylketones as irreversible inhibitors. Our data confirm that the halomethylketone unit is essential for the inhibitory activity. Moreover, addition of the halomethylketone moiety to reversible inhibitors turned them into irreversible inhibitors with IC(50) values in the nanomolar range. Overall, the results point out that these compounds might be useful pharmacological tools to explore physiological and pathological processes related to signaling pathways regulated by GSK-3 opening new avenues for the discovery of novel GSK-3 inhibitors.
Complete list of metadatas

https://hal-riip.archives-ouvertes.fr/pasteur-00686303
Contributor : Mariella Botta <>
Submitted on : Monday, April 9, 2012 - 8:24:23 PM
Last modification on : Monday, May 18, 2020 - 4:24:05 PM

Identifiers

Collections

Citation

Daniel I Perez, Valle Palomo, Concepción Pérez, Carmen Gil, Pablo D Dans, et al.. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.. Journal of Medicinal Chemistry, American Chemical Society, 2011, 54 (12), pp.4042-56. ⟨10.1021/jm1016279⟩. ⟨pasteur-00686303⟩

Share

Metrics

Record views

166